{"filings":[{"id":2105682,"accession_number":"0001171843-26-005317","cik":1626971,"company_name":"Corvus Pharmaceuticals, Inc.","ticker":"CRVS","form_type":"8-K","filed_at":"2026-08-06T20:02:32+00:00","items":["2.02","9.01"],"status":"ready","headline":"Corvus reports Q2 2026 net loss of $18.0M; cash $215.2M, runway into 2Q28","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $18.0M in Q2 2026 vs $8.0M in Q2 2025; R&D expenses $16.0M vs $7.9M.","Cash, equivalents and marketable securities $215.2M at June 30, 2026 (incl. $189.4M from Jan 2026 financing) vs $56.8M at Dec 2025; runway into 2Q28.","Soquelitinib Phase 3 PTCL and Phase 2 atopic dermatitis enrollment on track; plans to start hidradenitis suppurativa and asthma trials later 2026.","Invested $5.0M in Angel Pharma equity financing for soquelitinib trials in China.","Angel Pharma to initiate Phase 2 asthma trial early 2027; Corvus to start Phase 1b hidradenitis suppurativa and Phase 2 asthma trials later 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1044403085.9443158,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1802276,"accession_number":"0001104659-26-085790","cik":1626971,"company_name":"Corvus Pharmaceuticals, Inc.","ticker":"CRVS","form_type":"8-K","filed_at":"2026-07-22T20:02:21+00:00","items":["5.02"],"status":"ready","headline":"Director Ian T. Clark resigns from Corvus board effective July 22, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ian T. Clark delivered notice of resignation from the Board on July 21, 2026, effective July 22, 2026.","Clark served on the Board for over nine years; the Company thanked him for his contributions.","No replacement director has been announced as of the filing date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":1044403085.9443158,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1027078,"accession_number":"0001171843-26-004094","cik":1626971,"company_name":"Corvus Pharmaceuticals, Inc.","ticker":"CRVS","form_type":"8-K","filed_at":"2026-06-12T20:01:17+00:00","items":["5.07"],"status":"ready","headline":"Corvus stockholders re-elect Miller, Grais; ratify PwC as FY 2026 auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Richard A. Miller and Linda S. Grais elected as Class I directors with 58.3M and 53.2M votes for, respectively; 12.0M broker non-votes.","Ratification of PricewaterhouseCoopers as independent auditor: 72.9M for, 105.7k against, 51.8k abstain.","Non-binding advisory approval of NEO compensation: 58.9M for, 1.97M against, 64.3k abstain; 12.0M broker non-votes.","73.0M shares voted out of 84.1M shares outstanding as of record date April 16, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":1044403085.9443158,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":77445,"accession_number":"0001171843-26-003397","cik":1626971,"company_name":"Corvus Pharmaceuticals, Inc.","ticker":"CRVS","form_type":"8-K","filed_at":"2026-05-14T11:01:18+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Corvus reports positive Phase 1 soquelitinib data in atopic dermatitis; durable remissions without rebound","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["72-patient Phase 1 trial met safety and efficacy endpoints; no severe adverse events.","Cohort 4 (200 mg BID for 56 days): 75% achieved EASI 75, 25% achieved EASI 90, 33% IGA 0/1.","Biomarker data confirms ITK inhibition reduces Th2/Th17 cytokines and increases persistent Tregs.","Drug-free remission maintained in post-treatment follow-up (up to 90 days) with no disease rebound.","SIERRA1 Phase 2 trial for moderate-to-severe atopic dermatitis now enrolling ~200 patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1044403085.9443158,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94179,"accession_number":"0001171843-26-003154","cik":1626971,"company_name":"Corvus Pharmaceuticals, Inc.","ticker":"CRVS","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Corvus reports Q1 2026 net loss of $13.7M; cash $236.7M; soquelitinib trials advance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $13.7M in Q1 2026 vs net income $15.2M in Q1 2025; cash $236.7M (incl. $189.4M from Jan 2026 financing).","Phase 2 atopic dermatitis trial initiated (~200 patients, 4 dose cohorts, 12-week treatment).","Phase 3 registrational PTCL trial enrolling 150 patients; primary endpoint progression-free survival.","Partner Angel Pharma enrolling Phase 1b/2 atopic dermatitis trial in China; initial results expected late 2026.","New immunologic/biomarker data from Phase 1 to be presented at SID meeting on May 14, 2026."],"consensus_eps_estimate":-0.1457,"consensus_eps_actual":-0.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1044403085.9443158,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94178,"accession_number":"0001104659-26-047735","cik":1626971,"company_name":"Corvus Pharmaceuticals, Inc.","ticker":"CRVS","form_type":"8-K","filed_at":"2026-04-23T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Corvus Pharmaceuticals appoints Andrew C. Chan to board; Scott Morrison resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Andrew C. Chan appointed as Class II director, effective April 23, 2026, term through 2027 annual meeting.","Chan receives $35,000 annual retainer, $4,000 Nominating Committee fee, and initial option for 30,000 shares.","Scott Morrison resigned from board effective April 23, 2026 after over a decade of service.","Chan also appointed to the Nominating Committee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1044403085.9443158,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106369,"accession_number":"0001104659-26-027390","cik":1626971,"company_name":"Corvus Pharmaceuticals, Inc.","ticker":"CRVS","form_type":"8-K","filed_at":"2026-03-13T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Corvus ups at-the-market equity facility to $200M from $100M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amended Sales Agreement with Jefferies allows up to $200M in common stock sales, increased from $100M.","No shares sold under prior $100M agreement; new ATM offering uses customary terms.","Jefferies to receive up to 3.0% commission; agreements include representations and indemnification.","Prospectus supplement filed; sales may be in negotiated, block, or ATM transactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1044403085.9443158,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106368,"accession_number":"0001171843-26-001526","cik":1626971,"company_name":"Corvus Pharmaceuticals, Inc.","ticker":"CRVS","form_type":"8-K","filed_at":"2026-03-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Corvus Q4 net loss $12.3M; soquelitinib atopic dermatitis Ph1 75% EASI75; raises $189M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for Q4 2025 was $12.3M; R&D expenses $9.9M (up from $6.0M in Q4 2024).","Cash $56.8M at Dec 31, 2025; $189.4M net from Jan 2026 offering extends runway into Q2 2028.","Cohort 4 atopic dermatitis: 75% soquelitinib patients achieved EASI 75 vs 20% placebo; 33% IGA 0/1 vs 0%.","Initiated Phase 2 atopic dermatitis trial in Q1 2026; ~200 patients, four dose arms, 12-week treatment.","Phase 3 PTCL registrational trial enrolling; soquelitinib granted Fast Track and Orphan Drug Designation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1044403085.9443158,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106367,"accession_number":"0001104659-26-005968","cik":1626971,"company_name":"Corvus Pharmaceuticals, Inc.","ticker":"CRVS","form_type":"8-K","filed_at":"2026-01-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Corvus Pharmaceuticals prices $22.15/share public offering of ~9.1M shares for ~$188.3M net proceeds","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Upsized public offering of 7,900,677 shares at $22.15/share; underwriters fully exercised 30-day option for 1,185,101 additional shares.","Expected net proceeds of approximately $188.3 million after underwriting discounts and expenses.","Net proceeds to fund working capital and R&D for Phase 3 T cell lymphoma and Phase 2 atopic dermatitis, hidradenitis suppurativa, and asthma trials.","Offering expected to close on January 23, 2026; Jefferies and Goldman Sachs acted as lead underwriters."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1044403085.9443158,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106366,"accession_number":"0001104659-26-005035","cik":1626971,"company_name":"Corvus Pharmaceuticals, Inc.","ticker":"CRVS","form_type":"8-K","filed_at":"2026-01-20T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Corvus Pharmaceuticals suspends $100M ATM equity offering program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Suspended $100M at-the-market offering; zero shares sold prior to suspension.","Company notified Jefferies; no sales until new prospectus supplement or registration statement filed.","Sale Agreement remains in full force and effect despite suspension.","Company cites proposed registered underwritten public offering as context."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1044403085.9443158,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106365,"accession_number":"0001104659-26-004795","cik":1626971,"company_name":"Corvus Pharmaceuticals, Inc.","ticker":"CRVS","form_type":"8-K","filed_at":"2026-01-20T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Corvus reports positive Phase 1 soquelitinib data in atopic dermatitis; Phase 2 planned Q1 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cohort 4: 75% of soquelitinib patients achieved EASI 75 vs 20% placebo; 25% achieved EASI 90 vs 0% placebo.","Mean EASI reduction at day 56: 72% for soquelitinib vs 40% for placebo; separation statistically significant (p=0.035).","No new safety signals; AE rates 41.7% soquelitinib vs 50% placebo, all Grade 1-2, no dose modifications.","Activity seen in patients with prior systemic therapy including dupilumab/JAK inhibitors.","Plans to initiate Phase 2 trial in moderate-to-severe atopic dermatitis in Q1 2026 (approx. 200 patients, 4 arms)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1044403085.9443158,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122707,"accession_number":"0001171843-25-006973","cik":1626971,"company_name":"Corvus Pharmaceuticals, Inc.","ticker":"CRVS","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Corvus Pharms Q3 net loss $10.2M, cash $65.7M; soquelitinib trials advancing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $10.2M for Q3 2025, improved from $40.2M loss in Q3 2024 which included $32.8M non-cash warrant liability loss.","Cash, equivalents & marketable securities $65.7M as of Sept 30, 2025, up from $52.0M at Dec 31, 2024; funding expected into Q4 2026.","Completed enrollment in soquelitinib atopic dermatitis Phase 1 extension cohort 4 (200 mg BID, 8 weeks); data expected January 2026.","On track to initiate soquelitinib atopic dermatitis Phase 2 trial in early Q1 2026, targeting ~200 patients.","Phase 3 registrational trial of soquelitinib in relapsed/refractory PTCL enrolling; final Phase 1/1b results to be presented at ASH December 2025."],"consensus_eps_estimate":-0.1361,"consensus_eps_actual":-0.38,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1044403085.9443158,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122706,"accession_number":"0001104659-25-096103","cik":1626971,"company_name":"Corvus Pharmaceuticals, Inc.","ticker":"CRVS","form_type":"8-K","filed_at":"2025-10-02T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"David Moore joins Corvus board as Class III director through 2028; gets 30K option grant","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["David Moore appointed as Class III director, term expires at 2028 annual meeting.","Moore will serve on Compensation Committee ($6K/yr) and Nominating Committee ($4K/yr).","Receives $35K annual retainer and initial option to purchase 30,000 shares of common stock.","Appointment effective October 2, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":1044403085.9443158,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139393,"accession_number":"0001171843-25-005180","cik":1626971,"company_name":"Corvus Pharmaceuticals, Inc.","ticker":"CRVS","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Corvus Q2 net loss $8M, cash $74.4M; soquelitinib atopic dermatitis data shows deeper EASI reduction","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $8.0M for Q2 2025 vs $4.3M Q2 2024; R&D expenses $7.9M (up from $4.1M).","Cash, equivalents, securities $74.4M as of June 30, 2025; warrant exercise proceeds $35.7M in Q2.","Soquelitinib Phase 1 atopic dermatitis: cohort 3 mean EASI reduction 64.8% at day 28 vs 54.6% for cohorts 1-2 and 34.4% placebo.","50% of evaluable cohort 3 patients had ≥4 point itch reduction (PP-NRS) at day 28; Phase 2 on track by year-end.","Phase 3 PTCL registrational trial enrolling; cash expected to fund operations into Q4 2026."],"consensus_eps_estimate":-0.1426,"consensus_eps_actual":-0.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1044403085.9443158,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156978,"accession_number":"0001171843-25-003881","cik":1626971,"company_name":"Corvus Pharmaceuticals, Inc.","ticker":"CRVS","form_type":"8-K","filed_at":"2025-06-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Corvus Pharmaceuticals 2025 Annual Meeting results: all proposals approved","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected Class III directors Ian T. Clark (28.9M for, 10.4M withheld) and Peter A. Thompson (38.8M for, 0.4M withheld).","Ratified PricewaterhouseCoopers as independent auditor for FY2025: 53.1M for, 0.1M against, 0.1M abstain.","Non-binding advisory vote on named executive officer compensation passed: 37.1M for, 2.1M against, 63.8k abstain.","53.4M shares voted of 68.2M outstanding; broker non-votes of 14.1M on director and compensation proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":1044403085.9443158,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156977,"accession_number":"0001171843-25-003661","cik":1626971,"company_name":"Corvus Pharmaceuticals, Inc.","ticker":"CRVS","form_type":"8-K","filed_at":"2025-06-04T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Corvus soquelitinib Phase 1 atopic dermatitis data show statistically significant EASI improvement vs placebo","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Soquelitinib met primary endpoint with statistically significant EASI improvement vs placebo at day 28 (p=0.036).","Cohort 3 (200 mg BID) achieved 64.8% mean EASI reduction vs 34.4% for placebo.","In cohort 3, 50% of evaluable patients (4/8) had a ≥4-point itch reduction (PP-NRS) at day 28.","No safety signals; soquelitinib well tolerated with no DLTs and only one grade 1 AE (nausea).","Extension cohort (200 mg BID, 8-week treatment) enrollment has been initiated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1044403085.9443158,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156976,"accession_number":"0001171843-25-002981","cik":1626971,"company_name":"Corvus Pharmaceuticals, Inc.","ticker":"CRVS","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"Corvus Q1 net income $15.2M; soquelitinib atopic derm cohort 3 EASI −71.1% vs placebo −42.1%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income of $15.2M included $25.1M gain on warrant liability; R&D spend $7.5M vs $4.1M YoY.","Cash $44.2M at Mar 31; May warrant exercises added ~$31.3M, extending runway into Q4 2026.","Phase 1 atopic derm: cohort 3 (200 mg BID) achieved 71.1% mean EASI reduction vs 42.1% placebo; combined active vs placebo p=0.03.","No placebo patient achieved IGA 0/1 or EASI 75; soquelitinib well tolerated with no DLTs.","Protocol amended: replace cohort 4 with 24 patients (1:1 active/placebo) at 200 mg BID for 8 weeks; Phase 2 to start by year-end."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1044403085.9443158,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156975,"accession_number":"0001171843-25-002110","cik":1626971,"company_name":"Corvus Pharmaceuticals, Inc.","ticker":"CRVS","form_type":"8-K","filed_at":"2025-04-09T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Corvus Pharmaceuticals appoints Richard van den Broek to Board, effective April 8, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Richard van den Broek appointed as Class II director, term expiring at 2027 annual meeting.","Appointed to Audit Committee ($10k annual) and Nominating Committee ($4k annual) effective April 8, 2025.","Will receive $35k annual board retainer, prorated for current quarter, plus initial option for 30,000 shares.","Will enter into standard indemnification agreement for directors and officers.","Compensation consistent with company's non-employee director compensation program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1044403085.9443158,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175349,"accession_number":"0001171843-25-001689","cik":1626971,"company_name":"Corvus Pharmaceuticals, Inc.","ticker":"CRVS","form_type":"8-K","filed_at":"2025-03-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Corvus reports Q4 net loss $12.1M, cash $52M; atopic dermatitis Phase 1 shows 37% EASI 75 vs 0% placebo","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for Q4 2024 was $12.1M vs $6.7M in Q4 2023; full-year R&D expense $19.4M.","Cash, equivalents and securities $52.0M as of Dec 31, 2024, up from $27.1M, with runway into Q1 2026.","Atopic dermatitis Phase 1 cohorts 1-2: 26% of soquelitinib patients achieved IGA 0/1, 37% EASI 75 vs 0% placebo.","Phase 3 registrational trial of soquelitinib in PTCL is enrolling; Phase 2 ALPS trial initiated under NIAID.","Approximately $18.6M cash from early exercise of 5.3M warrants; 11.8M warrants remain outstanding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1044403085.9443158,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175348,"accession_number":"0001558370-25-000150","cik":1626971,"company_name":"Corvus Pharmaceuticals, Inc.","ticker":"CRVS","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Corvus reports soquelitinib Phase 1 atopic dermatitis data: 26% IGA 0/1, 37% EASI 75 vs 0% placebo","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["19 soquelitinib patients: 26% achieved IGA 0/1, 37% achieved EASI 75 at day 28.","Placebo group (n=7) had 0% achieving IGA 0/1 or EASI 75.","No significant safety issues; all 10 Cohort 2 patients completed 28-day full 200 mg once-daily dose.","Cohort 2 fully enrolled (N=16); full results from all four cohorts expected Q2 2025.","Soquelitinib 200 mg twice-daily dose being studied in Phase 3 for peripheral T cell lymphoma."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1044403085.9443158,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192288,"accession_number":"0001558370-24-016343","cik":1626971,"company_name":"Corvus Pharmaceuticals, Inc.","ticker":"CRVS","form_type":"8-K","filed_at":"2024-12-18T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Corvus reports positive interim Phase 1 soquelitinib data in atopic dermatitis; $12.7M warrant exercise","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Soquelitinib 100mg BID: mean EASI reduction 55.9% at Day 28 vs 27% placebo; 69.1% at Day 58 vs 19.1% placebo.","At Day 58, 90% of soquelitinib patients achieved EASI-50, 40% EASI-75, 10% EASI-90 vs 25%, 0%, 0% for placebo.","No significant safety issues; only Grade 1 nausea (1 patient) and COVID-19 (1 patient) reported.","Samlyn Capital exercised all warrants for 3,633,978 shares, generating ~$12.7M cash proceeds.","Initial Cohort 2 data (200mg once daily) in 12 patients consistent with Cohort 1; no treatment-related AEs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"market_cap_usd":1044403085.9443158,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192287,"accession_number":"0001171843-24-006284","cik":1626971,"company_name":"Corvus Pharmaceuticals, Inc.","ticker":"CRVS","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Corvus Q3 net loss $40.2M; soquelitinib atopic dermatitis interim data due Dec 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $40.2M for Q3 2024, including $32.8M non-cash warrant liability loss, vs $6.0M loss in Q3 2023.","Cash, equivalents and marketable securities $41.7M at Sep 30, 2024; projected year-end cash $38-39M.","October 2024 early warrant exercise raised $5.9M; approx. 15.4M warrants outstanding expiring June 2025.","Soquelitinib Phase 1 atopic dermatitis trial second cohort (200mg QD) enrolling; interim data expected Dec 2024.","Soquelitinib Phase 3 PTCL registrational trial enrolling at multiple sites; Orphan Drug and Fast Track granted."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.86,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1044403085.9443158,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192286,"accession_number":"0001558370-24-013518","cik":1626971,"company_name":"Corvus Pharmaceuticals, Inc.","ticker":"CRVS","form_type":"8-K","filed_at":"2024-10-23T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Corvus Pharmaceuticals enters sub-sublease for 20,916 sq ft in South San Francisco","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sublease term of 36 months from later of consent or Feb 1, 2025; option to extend up to May 2030.","Monthly base rent ranges $33,833 to $47,200 over lease term; prepaid rent of $231,235 applied to first three months.","Security deposit of $75,000 required; triple net lease with Subtenant paying proportionate share of expenses.","Premises at 901 Gateway Boulevard, South San Francisco, comprising third floor and first floor space.","Sublease is from NewLimit under existing prime sublease from Theravance Biopharma."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1044403085.9443158,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208781,"accession_number":"0001171843-24-004479","cik":1626971,"company_name":"Corvus Pharmaceuticals, Inc.","ticker":"CRVS","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Corvus reports Q2 loss; soquelitinib shows early activity in atopic derm, PTCL Phase 3 on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Early soquelitinib Phase 1 atopic dermatitis data (3 evaluable patients, 100 mg BID) show clinical activity and cytokine changes consistent with ITK inhibition.","Phase 3 registrational trial for soquelitinib in PTCL to start Q3 2024; updated Phase 1/1b data: 39% ORR (6 CRs, 3 PRs) in 23 evaluable patients.","Cash, cash equivalents and marketable securities $47.2M as of June 30, 2024; Q2 2024 net loss $4.3M vs $6.5M prior year; cash runway into Q4 2025.","Ciforadenant Phase 1b/2 trial in RCC met interim efficacy threshold; enrollment continues. New U.S. patent issued for ciforadenant.","Soquelitinib received Fast Track designation for relapsed/refractory PTCL; FDA pediatric waiver granted for T cell lymphoma indication."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1044403085.9443158,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226526,"accession_number":"0001171843-24-003444","cik":1626971,"company_name":"Corvus Pharmaceuticals, Inc.","ticker":"CRVS","form_type":"8-K","filed_at":"2024-06-14T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Corvus shareholders elect Scott Morrison to board, ratify PwC, approve exec pay","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Scott W. Morrison elected Class II director with 19,667,286 votes for, 5,398,946 withheld.","Ratification of PricewaterhouseCoopers as independent auditor for FY 2024: 35,776,658 for, 65,997 against.","Non-binding advisory vote to approve named executive officer compensation passed: 24,424,413 for, 413,670 against.","Record date April 18, 2024; 49,038,582 shares outstanding, 35,968,782 voted at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":1044403085.9443158,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226525,"accession_number":"0001193125-24-131920","cik":1626971,"company_name":"Corvus Pharmaceuticals, Inc.","ticker":"CRVS","form_type":"8-K","filed_at":"2024-05-06T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Corvus Pharmaceuticals raises $30.2M in registered direct offering with CEO participation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered Securities Purchase Agreement on May 1, 2024 to issue ~13.5M shares and warrants at $1.7312 per combined unit","Net proceeds expected ~$30.2M; closing expected May 6, 2024","Common warrants exercisable at $3.50/share, expiring June 30, 2025","CEO and existing institutional investors participated in the offering","Proceeds to be used for working capital, R&D, and general corporate purposes"],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1044403085.9443158,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226524,"accession_number":"0001171843-24-002569","cik":1626971,"company_name":"Corvus Pharmaceuticals, Inc.","ticker":"CRVS","form_type":"8-K","filed_at":"2024-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Corvus Q1 net loss $5.7M; soquelitinib PTCL ORR 39%; $30.6M financing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $5.7M in Q1 2024 vs $7.9M in Q1 2023; R&D expense $4.1M.","Cash $22.1M at March 31, 2024; plus $30.6M from May 6 financing; projected cash into Q4 2025.","Soquelitinib Phase 1/1b PTCL: 39% ORR (5 CRs, 4 PRs) in 23 evaluable patients; disease control 61%.","Phase 3 registrational trial for soquelitinib in PTCL planned to start Q3 2024.","Ciforadenant Phase 1b/2 in RCC met predefined efficacy threshold; enrollment continues."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1044403085.9443158,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226523,"accession_number":"0001193125-24-127611","cik":1626971,"company_name":"Corvus Pharmaceuticals, Inc.","ticker":"CRVS","form_type":"8-K","filed_at":"2024-05-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Corvus cuts ATM program ceiling from $90M to $8.2M; nearly all capacity used","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment reduces aggregate offering price under Jefferies ATM from $90M to $8.2M.","Approximately $8.1M of shares sold to date, leaving ~$100,000 remaining availability.","Program originally entered into on March 28, 2023; amendment dated May 1, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1044403085.9443158,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245524,"accession_number":"0001171843-24-001454","cik":1626971,"company_name":"Corvus Pharmaceuticals, Inc.","ticker":"CRVS","form_type":"8-K","filed_at":"2024-03-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Corvus Q4 net loss $6.7M; soquelitinib Orphan Drug; Phase 3 PTCL trial on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $6.7M in Q4 2023 vs $9.8M Q4 2022; cash $27.1M at Dec 31, 2023.","Soquelitinib Phase 1/1b: 7 of 21 evaluable PTCL patients had objective responses (4 CR, 3 PR).","FDA granted Orphan Drug Designation for soquelitinib in T cell lymphoma (Feb 2024).","Registrational Phase 3 PTCL trial expected to initiate Q3 2024; Phase 1 atopic dermatitis trial Q2 2024.","Appointed Jeffrey Arcara as Chief Business Officer to lead corporate strategy and business development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1044403085.9443158,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245523,"accession_number":"0001171843-24-000360","cik":1626971,"company_name":"Corvus Pharmaceuticals, Inc.","ticker":"CRVS","form_type":"8-K","filed_at":"2024-01-23T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Corvus Pharmaceuticals announces death of board member Edith P. Mitchell","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board member Dr. Edith P. Mitchell passed away; she served on Corvus board since September 2020.","Dr. Mitchell was a retired U.S. Air Force Brigadier General and clinical professor at Thomas Jefferson University.","Company issued press release expressing condolences; no succession or operational changes announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1044403085.9443158,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262999,"accession_number":"0001171843-23-006818","cik":1626971,"company_name":"Corvus Pharmaceuticals, Inc.","ticker":"CRVS","form_type":"8-K","filed_at":"2023-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Corvus reports Q3 net loss $6.0M, cash $32.2M; soquelitinib Phase 3 trial protocol finalized","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $6.0M vs $14.8M in Q3 2022; R&D expenses down to $4.0M from $10.4M.","Cash, equivalents and marketable securities $32.2M as of Sept 30, 2023 (Dec 31, 2022: $42.3M).","ATM program raised $7.8M net from 2.46M shares; FY 2023 cash burn guidance $22-23M.","Soquelitinib Phase 3 registrational trial for relapsed PTCL protocol finalized; enrollment expected Q2 2024; Phase 2 in RCC planned early 2024.","New soquelitinib data accepted for ASH Dec 2023; preclinical autoimmune/allergy data published."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1044403085.9443158,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280184,"accession_number":"0001171843-23-005595","cik":1626971,"company_name":"Corvus Pharmaceuticals, Inc.","ticker":"CRVS","form_type":"8-K","filed_at":"2023-09-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Corvus confirms soquelitinib Phase 3 trial for PTCL; initiation Q1 2024","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA End-of-Phase meeting completed; trial design confirmed: 150 patients, 1:1 randomization, primary endpoint PFS.","Enrollment of relapsed PTCL patients with ≤3 prior therapies; initiation expected in Q1 2024.","Company to host conference call on Sept 7, 2023 to discuss trial plan and business updates.","Soquelitinib is a selective ITK inhibitor; potential in hematologic cancers, solid tumors, autoimmune diseases."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1044403085.9443158,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280183,"accession_number":"0001171843-23-005102","cik":1626971,"company_name":"Corvus Pharmaceuticals, Inc.","ticker":"CRVS","form_type":"8-K","filed_at":"2023-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Corvus reports Q2 net loss $6.5M, soquelitinib shows 3 CR/3 PR in TCL; plans FDA meeting","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Soquelitinib Phase 1/1b: 3 complete, 3 partial responses in 20 evaluable TCL patients.","ALC >900/mL: 6/14 objective responses; 0/6 below 900. FDA meeting for Phase 3 in Q3.","Cash $37.0M as of June 30, 2023; projected $28-30M year-end, funding into H2 2024.","Q2 R&D expense $4.0M (down from $4.9M); net loss $6.5M vs $8.4M in Q2 2022.","Ciforadenant Phase 1b/2 in RCC initial data expected year-end 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.31,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1044403085.9443158,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298721,"accession_number":"0001171843-23-004019","cik":1626971,"company_name":"Corvus Pharmaceuticals, Inc.","ticker":"CRVS","form_type":"8-K","filed_at":"2023-06-21T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Corvus Pharmaceuticals holds 2023 annual meeting; elects directors and ratifies auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders elected Richard A. Miller, M.D. and Linda S. Grais, M.D., J.D. as Class I directors for three-year terms.","Ratified PricewaterhouseCoopers as independent auditor for FY2023 with 35.9M votes for, 0.1M against.","Non-binding advisory vote on executive compensation passed with 25.6M for, 0.4M against.","Total shares voted: 36.2M of 46.6M outstanding (77.6% turnout)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":1044403085.9443158,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298720,"accession_number":"0001171843-23-003041","cik":1626971,"company_name":"Corvus Pharmaceuticals, Inc.","ticker":"CRVS","form_type":"8-K","filed_at":"2023-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Corvus reports Q1 net loss of $7.9M; CPI-818 shows 6/13 ORR in ALC>900 TCL patients","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $7.9M vs $8.3M in Q1 2022; cash & securities $34.5M as of March 31, 2023.","CPI-818 Phase 1/1b TCL: 2 CR, 1 nodal CR, 3 PR among 19 evaluable; 9 patients remain on therapy.","ALC>900 biomarker selected 6/13 ORR; median PFS 19.9 months for ALC>900 vs 2.1 months for <900.","CFO expects FY2023 net cash use of $19-22M; projected year-end cash of $20-23M funding into 2024.","Plans to meet with FDA in Q3 2023 to discuss potential registrational Phase 3 trial for CPI-818."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1044403085.9443158,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298719,"accession_number":"0001171843-23-002460","cik":1626971,"company_name":"Corvus Pharmaceuticals, Inc.","ticker":"CRVS","form_type":"8-K","filed_at":"2023-04-24T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Corvus Pharmaceuticals regains Nasdaq minimum bid price compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq deficiency notice on Oct 25, 2022 for bid price below $1.00.","Compliance period was 180 days, expiring April 24, 2023.","On April 21, 2023, Nasdaq confirmed compliance after 10 consecutive business days of closing bid price at or above $1.00 from April 6-20.","Matter is now closed; no further action needed on listing requirement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1044403085.9443158,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298718,"accession_number":"0001171843-23-002089","cik":1626971,"company_name":"Corvus Pharmaceuticals, Inc.","ticker":"CRVS","form_type":"8-K","filed_at":"2023-04-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Corvus Pharma reduces CEO salary from $300K to $34,840; grants 800K options","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO base salary cut to $34,840/year effective March 31, 2023, from $300,000.","Option to purchase 800,000 shares granted, vesting monthly over 36 months.","Compensation Committee approved the changes on March 29, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1044403085.9443158,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":318914,"accession_number":"0001193125-23-082785","cik":1626971,"company_name":"Corvus Pharmaceuticals, Inc.","ticker":"CRVS","form_type":"8-K","filed_at":"2023-03-29T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Corvus terminates ATM equity programs with Jefferies","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Terminated 2020 Sales Agreement (up to $50M) and 2021 Sales Agreement (up to $40M) with Jefferies LLC effective March 28, 2023.","Both at-the-market offering programs are no longer available for use.","No reason for termination provided in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1044403085.9443158,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":318913,"accession_number":"0001171843-23-001948","cik":1626971,"company_name":"Corvus Pharmaceuticals, Inc.","ticker":"CRVS","form_type":"8-K","filed_at":"2023-03-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Corvus reports Q4 net loss of $9.8M; identifies predictive biomarker for CPI-818 in T-cell lymphoma","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $42.3M at Dec 31, 2022 (from $69.5M); 2023 operating burn guided $19-22M with year-end cash $20-23M.","Q4 2022 net loss $9.8M vs $9.2M year ago; R&D expense $4.1M.","CPI-818 Phase 1/1b: ALC >900 biomarker identified; 4/8 biomarker-positive patients had objective responses.","Median PFS 28.1 months in ALC>900 patients vs 2.1 months in ALC<900 patients (n=13 evaluable).","Atopic dermatitis trial delayed to conserve cash; FDA meeting for Phase 3 lymphoma trial planned for 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1044403085.9443158,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":318912,"accession_number":"0001171843-23-001602","cik":1626971,"company_name":"Corvus Pharmaceuticals, Inc.","ticker":"CRVS","form_type":"8-K","filed_at":"2023-03-13T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Corvus Pharmaceuticals confirms no cash or securities at Silicon Valley Bank","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Corvus Pharmaceuticals, on March 10, 2023, stated it does not hold cash deposits or securities at Silicon Valley Bank.","The disclosure addresses investor concerns after Silicon Valley Bank's collapse.","Company's liquidity unaffected by SVB failure; no cash or securities at risk."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1044403085.9443158,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":337146,"accession_number":"0001171843-22-007074","cik":1626971,"company_name":"Corvus Pharmaceuticals, Inc.","ticker":"CRVS","form_type":"8-K","filed_at":"2022-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Corvus Q3 net loss $14.8M; cash $49.6M, CPI-818 data at ASH","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $14.8M for Q3 2022 vs $10.7M Q3 2021; R&D expense $10.4M (+$3.4M).","Cash, equivalents & securities $49.6M at Sep 30, 2022; projected year-end $40.5-42.5M.","CPI-818 200 mg cohort: 1 CR lasting 25 months, 1 nodal CR 16 months, 1 PR; new data at ASH Dec 2022.","Ciforadenant Phase 1b/2 in first-line RCC initiated with KCRC; up to 60 patients.","IND approved in China for mupadolimab Phase 1/1b combo with pembrolizumab in lung/head & neck cancers."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.62,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1044403085.9443158,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":337144,"accession_number":"0001171843-22-007083","cik":1626971,"company_name":"Corvus Pharmaceuticals, Inc.","ticker":"CRVS","form_type":"8-K/A","filed_at":"2022-11-03T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Corvus adopts annual advisory say-on-pay vote after stockholder vote","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board sets annual frequency for non-binding advisory votes on executive compensation.","Policy effective until next required stockholder vote on frequency, no later than 2028 annual meeting.","Decision follows stockholder advisory vote and board recommendation from June 2022 meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":1044403085.9443158,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":337145,"accession_number":"0001171843-22-006866","cik":1626971,"company_name":"Corvus Pharmaceuticals, Inc.","ticker":"CRVS","form_type":"8-K","filed_at":"2022-10-28T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Corvus Pharma receives Nasdaq delisting notice for bid price below $1.00","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Corvus on Oct 25, 2022 that its stock failed to maintain minimum $1.00 bid price for 30 consecutive business days.","Company has 180 calendar days, until April 24, 2023, to regain compliance by closing at $1.00+ for 10 consecutive days.","If non-compliance persists, Corvus may transfer to Nasdaq Capital Market and seek an additional 180-day grace period.","Corvus may consider a reverse stock split or other options to cure the deficiency but no assurance of success."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1044403085.9443158,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":354515,"accession_number":"0001171843-22-005458","cik":1626971,"company_name":"Corvus Pharmaceuticals, Inc.","ticker":"CRVS","form_type":"8-K","filed_at":"2022-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Corvus prioritizes CPI-818; pauses mupadolimab Phase 2; Q2 net loss $8.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and marketable securities $56.7M as of June 30, 2022, down from $69.5M at Dec 31, 2021.","Net loss $8.4M for Q2 2022 vs $11.8M for Q2 2021; R&D expenses fell to $4.9M from $9.1M.","CPI-818 200 mg cohort: 1 CR lasting 25 months, 1 nodal CR 16 months, 1 PR ongoing; no DLTs up to 600 mg.","Pausing start of randomized Phase 2 trial of mupadolimab in front-line NSCLC to focus on CPI-818 and conserve capital.","Expects cash runway into early 2024; full year 2022 net cash use $27-29M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1044403085.9443158,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":372497,"accession_number":"0001171843-22-004406","cik":1626971,"company_name":"Corvus Pharmaceuticals, Inc.","ticker":"CRVS","form_type":"8-K","filed_at":"2022-06-17T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Corvus shareholders elect all director nominees, ratify auditor, approve say-on-pay","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Class III directors: Ian T. Clark (20.9M for), Elisha Gould III (22.6M for), Peter Thompson (17.1M for).","Ratified PricewaterhouseCoopers as fiscal 2022 auditor with 35.3M votes for.","Advisory vote on executive compensation approved (22.6M for, 0.4M against).","Shareholders selected 1-year frequency for future say-on-pay votes (22.5M for 1 year)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1044403085.9443158,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":372496,"accession_number":"0001171843-22-003326","cik":1626971,"company_name":"Corvus Pharmaceuticals, Inc.","ticker":"CRVS","form_type":"8-K","filed_at":"2022-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Corvus Pharma Q1 net loss $8.3M; cash $62.9M; Phase 2 NSCLC trial planned","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $8.3M for Q1 2022 vs $11.6M in Q1 2021; R&D expenses down to $5.1M from $8.2M.","Cash, cash equivalents and marketable securities $62.9M as of March 31, 2022 vs $69.5M at Dec 31, 2021.","Plans Phase 2 randomized trial of mupadolimab + chemo in front-line NSCLC in 2022 with ~150 patients.","Phase 1b/2 ciforadenant + ipilimumab/nivolumab in front-line RCC to start Q3 2022 via Kidney Cancer Consortium.","Phase 1/1b CPI-818 (ITK inhibitor) continues enrolling T-cell lymphoma patients; data expected later 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1044403085.9443158,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":391318,"accession_number":"0001171843-22-001774","cik":1626971,"company_name":"Corvus Pharmaceuticals, Inc.","ticker":"CRVS","form_type":"8-K","filed_at":"2022-03-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Corvus reports Q4 net loss of $9.2M, cash $69.5M; plans Phase 2 trials in NSCLC and RCC","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q4 2021 $9.2M vs net income $27.3M in Q4 2020 (incl $37.5M deconsolidation gain).","Full year 2021 net loss $43.2M vs $6.0M in 2020; R&D expenses $29.1M down from $31.8M.","Cash, equivalents and securities $69.5M at Dec 31, 2021, up from $44.3M; FY2022 cash burn guidance $34-36M.","Plans randomized Phase 2 trial of mupadolimab plus chemo in front-line NSCLC (150 patients).","Plans Phase 2 trial of ciforadenant plus ipilimumab/nivolumab in front-line RCC with Kidney Cancer Consortium."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1044403085.9443158,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":409506,"accession_number":"0001104659-21-132583","cik":1626971,"company_name":"Corvus Pharmaceuticals, Inc.","ticker":"CRVS","form_type":"8-K","filed_at":"2021-11-02T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Corvus enters $40M ATM equity offering with Jefferies LLC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sales agreement for up to $40M in common stock, Jefferies as sales agent.","Jefferies receives up to 3% commission on gross proceeds from sales.","Sales may occur through Nasdaq, block trades, or privately negotiated transactions.","Company may suspend or terminate the agreement at any time; no obligation to sell shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1044403085.9443158,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":409505,"accession_number":"0001171843-21-007353","cik":1626971,"company_name":"Corvus Pharmaceuticals, Inc.","ticker":"CRVS","form_type":"8-K","filed_at":"2021-11-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Corvus Q3 net loss $10.7M, cash $76.3M; mupadolimab trials enrolling","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for Q3 2021 was $10.7M vs $9.8M in Q3 2020; R&D expenses $7.0M vs $6.6M.","Cash, equivalents and marketable securities $76.3M at Sept 30, 2021, up $32.0M from Dec 31, 2020; FY 2021 cash burn guided ~$36M.","Two Phase 1b/2 trials of mupadolimab + pembrolizumab enrolling: relapsed NSCLC (n=15) and HPV+ HNSCC (n=15); results expected 2022.","Angel Pharma received IND approval in China for CPI-818 Phase 1/1b in T-cell lymphoma; trial to open early 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.84,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1044403085.9443158,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":428437,"accession_number":"0001171843-21-005373","cik":1626971,"company_name":"Corvus Pharmaceuticals, Inc.","ticker":"CRVS","form_type":"8-K","filed_at":"2021-08-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Corvus Q2 net loss $11.8M; discontinues COVID-19 trial, cuts cash burn guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents and marketable securities $66.5M at June 30, 2021, up from $44.3M at Dec 31, 2020.","Net loss $11.8M for Q2 2021 vs $10.6M in Q2 2020; R&D expenses $9.1M (up $1.2M YoY).","Discontinued Phase 3 mupadolimab COVID-19 trial in July 2021 (no safety/efficacy issue); full-year cash burn guidance cut ~$11M to $35-37M.","Enrolling Phase 1b/2 trial of mupadolimab plus pembrolizumab in HPV+ oropharyngeal cancer; results expected by year-end 2021.","Angel Pharmaceuticals filed IND in China for CPI-818 Phase 2 in T-cell lymphomas; ciforadenant Phase 2 RCC trial planned with Kidney Cancer Consortium."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.61,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1044403085.9443158,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2021-08-02T23:59:59+00:00|428437"}